ClinicalTrials.gg
TerminatedNCT06209736Updated Nov 2, 2026

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

A Phase 2 interventional study of OMS906 study drug in C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis, sponsored by Omeros Corporation. Terminated at 6 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Omeros Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated for strategic reasons related to the molecule's recent acquisition
Updated Nov 2, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Read the detailed description

This is a multicenter, open-label, uncontrolled, non-comparative, fixed-dose study. The primary objective is to assess safety and tolerability of OMS906 in patients with C3G or idiopathic ICGN, both complement-mediated disorders. Patients will receive 5 mg/kg administered as intravenous (IV) infusions at 4-week intervals. The study will enroll up to approximately 20 patients with C3G or ICGN. Safety will be evaluated in all patients and by disease cohort. Preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) will be evaluated by disease cohort.

02

Conditions studied

  • C3 Glomerulopathy
  • Idiopathic Immune Complex-Mediated Glomerulonephritis

Browse trials for

Keywords

  • C3G
  • ICGN
03

In context

Glomerulonephritis

115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.

This study's enrollment of 3 is below the median of 50 across 87 interventional studies indexed under Glomerulonephritis.

Browse Glomerulonephritis studies →

Lead sponsor

Omeros Corporation is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults 18 years and older.
  2. Competent to provide and has completed informed consent procedures.
  3. Diagnosis of C3G, including dense deposit disease, or ICGN confirmed by within 36 months of screening.
  4. Two 24-hour UPCR ≥ 0.8 gm/gm with the 2 collections separated by 14 - 28 days.
  5. estimated by the CKD-EPI equation ≥ 45 mL/min/1.73 m2.
  6. Serum C3 concentration less than the lower limit of laboratory normal during screening.
  7. Must be on stable maximally tolerated or allowed dose of ACE inhibitor or ARB for at least 90 days.
  8. If receiving a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, must be on a stable dose for at least 90 days.
  9. If receiving mycophenolate mofetil, a mineralocorticoid receptor antagonist, or a , must be on stable dose for at least 90 days.
  10. Have current vaccination status for Neisseria meningitidis, Streptococcus pneumonia and Haemophilus influenza (where available) and agree to maintain vaccination throughout the study.

    Patients who have not received these vaccinations at the time of screening may be vaccinated at any time prior to 2 weeks before the first study drug administration. Vaccine serotypes will be chosen by the local standard of care and serotype prevalence.

  11. Female patients of must have a negative highly sensitive pregnancy test at screening and prior to each dose of OMS906.
  12. Females must use highly effective * to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.
  13. Males must use highly effective birth control* with a female partner to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. History of major organ transplant or hematopoietic stem cell/marrow transplant.
  2. Have known congenital deficiency of any of complement factors C1q, C1r, C1s, C2 or C4.
  3. Have rapidly progressing glomerulonephritis defined as a 50% or greater decline in the within 3 months with renal findings of glomerular crescent formation seen in at least 50% of glomeruli.
  4. Have renal biopsy findings showing interstitial fibrosis/tubular atrophy of more than 50%.
  5. Immunodeficiency or treatment with agents (except mycophenolate mofetil or at the prednisone equivalent of ≤ 7.5 mg/day in patients with C3G only) within 90 days of screening.
  6. Treatment with rituximab within 6 months of screening.
  7. Resting blood pressure > 140/90 mmHg during screening.
  8. History of any active within 5 years of screening except non-melanoma skin cancers.
  9. History of monoclonal gammopathy of unknown significance or any disorder.
  10. Elevation of liver function tests, defined as total > 2 × (ULN), direct bilirubin > 1.5 × ULN, and elevated transaminases, (ALT) or aspartate aminotransferase (AST) > 2 × ULN.
  11. History of any severe reactions to other monoclonal antibodies or included in the OMS906 preparation.
  12. Significant active bacterial or viral infection within the 2 weeks prior to screening including Covid-19 infection.
  13. Use of any other complement inhibitor within 6 months prior to the screening visit.
  14. Have , , or untreated infection.
  15. Pregnant, planning to become pregnant, or nursing female patient.
  16. Recent surgery requiring general anesthesia within the 2 weeks prior to screening or expected to have surgery requiring general anesthesia during the treatment period.
  17. History of any significant medical, neurologic, or psychiatric disorder that in the opinion of the investigator would make the patient unsuitable for participation in the study.
  18. Treatment with any medicinal product or investigational device within 30 days (or within 5 × its half-life in days, whichever is the longer period) prior to screening, or participation in another concurrent clinical trial involving a therapeutic intervention. Participation in observational and/or registry studies is permitted.
  19. Unable or unwilling to comply with the requirements of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Study Drug OMS906

    Repeat-dose OMS906 5 mg/kg IV administration at 4-week intervals

    Drug: OMS906 study drug

Interventions

  • OMS906 study drug dose 5mg/kg IV administration at 4-week internals

    Also known as: OMS906

06

What researchers measure

Primary outcomes

  1. To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN.

    Number of participants with Adverse Events following dosing of OMS906.

    Time frame: 48 weeks

Secondary outcomes

  1. Change in proteinuria measured by 24-hour urine protein/creatinine ratio (UPCR).

    Change from baseline in proteinuria measured as 24-hour UPCR at 12, 24, and 48 weeks.

    Time frame: 12, 24, 48 weeks

  2. Change in proteinuria measured by 24-hour urine protein excretion (UPE).

    Change from baseline in proteinuria measured as 24-hour UPE at 12, 24, and 48 weeks.

    Time frame: 12, 24, and 48 weeks.

  3. Change in proteinuria measured as 24-hour urine albumin excretion (UAE).

    Change from baseline in proteinuria measured as 24-hour UAE at 12, 24, and 48 weeks.

    Time frame: Time Frame: 12, 24, and 48 weeks.

  4. Change in proteinuria measured as 24-hour urine albumin/creatinine ratio (UACR).

    Change from baseline in proteinuria measured as 24-hour UACR at 12, 24, and 48 weeks.

    Time frame: 12, 24, and 48 weeks.

  5. Incidence of participants with a change from baseline of estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at 24 and 48 weeks.

    Number and % of participants with a change from baseline of estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at 24 and 48 weeks.

    Time frame: 24 and 48 weeks

  6. Incidence of participants with a change from baseline serum creatinine concentration at 24 and 48 weeks.

    Number and % of participants with a change from baseline serum creatinine concentration at 24 and 48 weeks.

    Time frame: 24 and 48 weeks

  7. Pharmacodynamics (PD) of multiple-dose administration of OMS906.

    Mature Complement Factor D (CFD) concentration.

    Time frame: 48 weeks

  8. Pharmacokinetics (PK) of multiple-dose administration of OMS906 - Cmax.

    PK parameters including OMS906 maximum concentration - peak plasma concentration (Cmax).

    Time frame: 48 weeks

  9. Pharmacokinetics (PK) of multiple-dose administration of OMS906 - AUC.

    PK parameters - Area under the plasma concentration vs time curve (AUC).

    Time frame: 48 weeks

  10. OMS906 anti-drug antibodies (ADA).

    Number of patients with measurable ADA.

    Time frame: 48 weeks

07

Study locations

6 sites
  • Omeros Investigational Site
    Kaunas, Lithuania
  • Omeros Investigational Site
    Vilnius, Lithuania
  • Omeros Investigational Site
    Auckland, New Zealand
  • Omeros Investigational Site
    Lodz, Poland
  • Omeros Investigational Site
    Leicester, United Kingdom
  • Omeros Investigational Site
    Newcastle upon Tyne, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Apr 2026, 25 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Apr 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 17, 2024
StartActual
Mar 1, 2024
Primary completionActual
Apr 14, 2026was Jan 2026
CompletionActual
Apr 14, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was terminated for strategic reasons related to the molecule's recent acquisition
changed Nov 2, 2026
Primary completion
Jan 2026→Apr 14, 2026 (actual)
Nov 2, 2026
Enrollment
20 (estimated)→3 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Terminated
    Why stopped The study was terminated for strategic reasons related to the molecule's recent acquisition
    Primary completion Jan 2026→Apr 14, 2026 (now actual)
    Enrollment 20 (estimated)→3 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06209736
Lead sponsor
Omeros Corporation
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Mar 1, 2024
Primary completion
Apr 14, 2026
Completion
Apr 14, 2026
Last update
Nov 2, 2026

Study contacts

Steve Whitaker, MD
study director · Omeros Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zaltenibart

Start the discussion